Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.57 |
| ▸ | KDM1A | O60341 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740683 | 1.00 | MAOA (1.00) | MAOADRD2HSD17B10TSHRKDM4E | |
| SCHEMBL10029584 | 1.00 | MAOA (1.00) | MAOADRD2HSD17B10TSHRKDM4E | |
| SCHEMBL29476085 | 1.00 | MAOA (1.00) | MAOADRD2HSD17B10TSHRKDM4E | |
| SCHEMBL7938058 | 1.00 | MAOA (1.00) | MAOADRD2HSD17B10TSHRKDM4E | |
| Bromide SCHEMBL3757469 | 0.98 | MAOA (1.00) | MAOADRD2HSD17B10TSHRKDM4E | |
| Bromide SCHEMBL29544330 | 0.98 | MAOA (1.00) | MAOADRD2HSD17B10TSHRKDM4E | |
| Phenol SCHEMBL27602371 | 0.89 | MAOA (0.79) | MAOADRD2HSD17B10TSHRKDM4E | |
| Phenol SCHEMBL27602370 | 0.89 | MAOA (0.79) | MAOADRD2HSD17B10TSHRKDM4E | |
| Phenol SCHEMBL28752297 | 0.87 | MAOA (0.79) | MAOADRD2HSD17B10TSHRKDM4E | |
| Phenol SCHEMBL27621020 | 0.87 | MAOA (0.79) | MAOADRD2HSD17B10TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | LIBRAGEN (FR) | 2014-03-27 | — | — | US | claimed |
| CN-101611148-A | Water-soluble phenolic derivatives for cosmetic and therapeutic applications on the skin | LIBRAGEN (FR) | 2009-12-23 | — | — | CN | claimed |
| EP-2027279-A2 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | Libragen (FR) | 2009-02-25 | — | — | EP | claimed |
| WO-2007144368-A2 | WATER SOLUBLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS | LIBRAGEN (FR) | 2007-12-21 | — | — | WO | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673782-B1 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORP (US) | 2000-06-14 | — | — | EP | claimed |
| US-20240246965-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | EQUINORM LTD | 2024-07-25 | — | — | US | disclosed |
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4313985-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE | Equinorm Ltd (FI) | 2024-02-07 | — | — | EP | disclosed |
| CN-117412975-A | Heterocyclic compounds and their use | 伊科诺姆有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-109485628-B | Chiral polyamide membrane and preparation method and application thereof | 中国药科大学 | 2022-07-22 | — | — | CN | disclosed |
| US-5639887-A | MULTIDRUG RESISTANT CELLS; INCREASE CELL SENSITIVITY TO ANTICANCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| US-5561141-A | POTENTIATE ACTIVITY OF ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1996-10-01 | — | — | US | disclosed |
| US-5550149-A | SULFUR-CONTAINING COMPOUNDS THAT ARE EFFECTIVE IN POTENTIATING THE ACTIVITY OF CHEMOTHERAPEUTIC ANTI-CANCER AGENTS BY INCREASING SENSITIVITY OF MULTI-DRUG RESISTANT CELLS | AMERICAN CYANAMID COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| US-5387685-A | MDR reversal agents | AMERICAN CYANAMID COMPANY | 1995-02-07 | — | — | US | disclosed |
| EP-0634401-A1 | MDR reversal agents | AMERICAN CYANAMID COMPANY (US) | 1995-01-18 | — | — | EP | disclosed |
| WO-1993012113-A1 | 3-SUBSTITUTED IMIDAZO (1,5-a) AND IMIDAZO (1,5-a)-TRIAZOLO (1,5-c) QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY | THE UPJOHN COMPANY (US) | 1993-06-24 | — | — | WO | disclosed |
| WO-1993012091-A1 | D- AND L-1,2,3,4-TETRAHYDRO-ISOQUINOLINE-1-CARBOXYLIC ACIDS AND THEIR DERIVATIVES CONTAINING URETHANE-TYPE N-PROTECTING GROUPS AS WELL AS A PROCESS FOR PREPARING THEM AND THE CORRESPONDING RACEMATES | Gyógyszerkutató Intézet Kft. (HU) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246965-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | CNR1, CNR2, OPRK1 | MAOA 220/4885DRD2 43/4885HSD17B10 756/4885 |
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | UGGT1, TYR, G6PD | MAOA 688/4885DRD2 3201/4885HSD17B10 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.